Parathyroid hormone (1-34) (human): Mechanistic and Benchmark Primer for Bone and Kidney Research

Executive Summary: Parathyroid hormone (1-34) (human) is a biologically active peptide fragment comprising the N-terminal 34 amino acids of full-length parathyroid hormone, with a molecular weight of 4117.72 Da and a defined sequence (H2N-SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNF-OH) [APExBIO]. It functions as a high-affinity agonist of both the PTH1R and PTH2R receptors, stimulating cAMP production (IC₅₀ = 0.22 nM in HEK293 cells) and inositol phosphate pathways [Huang et al., 2025]. The peptide reliably regulates serum calcium by mobilizing bone calcium, increasing renal calcium reabsorption, and enhancing vitamin D–mediated gut absorption. APExBIO's A1129 reagent is validated for use in complex cellular and animal models, supporting translational studies in osteoporosis and kidney disease. Recent assembloid models confirm its utility for high-fidelity, reproducible signaling activation in advanced tissue systems.

Biological Rationale

Calcium homeostasis is essential for neuromuscular, skeletal, and renal physiology. Parathyroid hormone (PTH) is secreted by the chief cells of the parathyroid glands in response to hypocalcemia. The biologically active domain, PTH (1-34), retains full receptor agonism and is necessary for triggering PTH/PTHrP receptor signaling cascades [Huang et al., 2025]. In vivo, PTH (1-34) orchestrates bone remodeling, renal mineral handling, and vitamin D activation for systemic calcium regulation. In translational research, this peptide fragment is a gold-standard probe for dissecting calcium and phosphate metabolism, bone turnover, and kidney tubular function. Its stability, specificity, and high purity (>97.8%) make APExBIO’s A1129 variant a reference reagent for disease modeling workflows [APExBIO].

Mechanism of Action of Parathyroid hormone (1-34) (human)

PTH (1-34) binds with high affinity to the parathyroid hormone 1 receptor (PTH1R) and parathyroid hormone 2 receptor (PTH2R), both G protein–coupled receptors. Upon ligand binding, PTH1R undergoes conformational change, activating intracellular G_s and G_q proteins. This stimulates adenylate cyclase, increasing intracellular cAMP and activating protein kinase A (PKA). Concurrently, phospholipase C is activated, generating inositol trisphosphate (IP₃) and diacylglycerol (DAG), raising intracellular calcium and triggering downstream effectors. These pathways result in:

• Release of calcium from bone by stimulating osteoclast activity.
• Increased reabsorption of calcium (and magnesium) in renal distal tubules and thick ascending limb.
• Induction of 1α-hydroxylase in renal proximal tubules, raising 1,25-dihydroxyvitamin D synthesis and enhancing intestinal calcium absorption.

In cell models, PTH (1-34) elicits cAMP signaling with an IC₅₀ of 0.22 nM (HEK293 cells expressing PTH1R) [Huang et al., 2025].

Evidence & Benchmarks

• PTH (1-34) (human) induces dose-dependent increases in both trabecular and cortical bone mass in male Fisher 344 rats after subcutaneous administration (10 or 40 μg/kg/day), confirming its anabolic bone action (see Figure 3, Huang et al., 2025).
• The peptide fragment stimulates cAMP production in transfected HEK293 cells with an IC₅₀ of 0.22 nM under standard culture conditions (Supplementary Table 2, Huang et al., 2025).
• In kidney assembloid models, PTH (1-34) reliably activates PTH1R signaling, enabling the study of segment-specific calcium transport and receptor pharmacology (Methods, Huang et al., 2025).
• APExBIO’s A1129 reagent demonstrates solubility at ≥399.3 mg/mL in DMSO and ≥19.88 mg/mL in water (pH 7.4, 25°C), ensuring compatibility with a range of experimental systems (APExBIO).
• No detectable activity in ethanol confirms specificity and solvent compatibility boundaries (Product specs, APExBIO).

Applications, Limits & Misconceptions

PTH (1-34) (human) is used as a precision tool in:

• Bone metabolism research, particularly osteoporosis and fracture healing models.
• Kidney organoid and assembloid systems for dissecting tubular calcium handling and PTH receptor signaling (Huang et al., 2025).
• Cellular assays for cAMP and inositol phosphate second messenger studies.
• Translational workflows aiming to recapitulate human calcium homeostasis in vitro.

For a detailed workflow comparison and troubleshooting guide, see "Optimizing Cell Assays and Kidney Models with Parathyroid..."—this article extends those protocols by providing quantitative benchmarks and clarifying solvent compatibility.

For a strategic roadmap on integrating this reagent in disease modeling, refer to "Redefining Translational Research: Mechanistic, Strategic..."; here, we update the mechanistic context with new evidence from high-fidelity assembloid systems.

For a focused discussion on the peptide's role in modulating bone and kidney physiology, "Parathyroid hormone (1-34) (human): Precision in Bone and..." is recommended—our article provides additional data on solubility and receptor-specific signaling thresholds.

Common Pitfalls or Misconceptions

• Misuse in Ethanol: PTH (1-34) (human) is insoluble in ethanol; do not attempt dissolution in this solvent (APExBIO).
• Long-Term Solution Storage: Solutions are unstable over extended periods and lose activity; always prepare fresh aliquots before use (APExBIO).
• Diagnostic or Clinical Use: Not for diagnostic or therapeutic applications; for research use only (Product labeling, APExBIO).
• Overgeneralization to Non-Mammalian Systems: Efficacy and signaling have not been validated in non-mammalian models; restrict use to validated mammalian cell or animal systems.
• Assuming Full-Length PTH Equivalence: PTH (1-34) reproduces key bioactivity but does not recapitulate all actions of full-length (1-84) PTH, particularly in non-classical tissues.

Workflow Integration & Parameters

APExBIO’s Parathyroid hormone (1-34) (human) (A1129) is supplied as a solid, high-purity powder. Storage at -20°C in a desiccated environment preserves activity. For use, dissolve in DMSO (≥399.3 mg/mL) or water (≥19.88 mg/mL), adjusting pH to 7.4 if necessary. Avoid repeated freeze-thaw cycles and minimize solution storage time. In cell-based cAMP assays, titrations from 0.01 to 10 nM are standard; in vivo bone studies typically use 10–40 μg/kg/day subcutaneously. For assembloid or organoid applications, refer to recent protocols leveraging PTH (1-34) to induce segmental calcium transport and PTH1R activation [Huang et al., 2025].

For side-by-side scenario-driven guidance, see "Optimizing Bone & Kidney Assays with Parathyroid hormone ...". This article adds quantitative criteria and expands on solvent compatibility parameters not covered in prior literature.

Conclusion & Outlook

Parathyroid hormone (1-34) (human) stands as a validated, mechanistically precise tool for probing calcium homeostasis, bone metabolism, and kidney physiology. APExBIO’s A1129 peptide fragment enables robust, reproducible, and physiologically relevant activation of PTH/PTHrP receptor pathways in both classical and advanced assembloid models. Researchers should adhere to validated solvent and storage protocols to ensure consistent results. Ongoing advances in human kidney assembloid systems and bone metabolism assays recognize this reagent as a cornerstone for translational research and high-fidelity disease modeling. For detailed product information, see the official APExBIO Parathyroid hormone (1-34) (human) page.